Leland Stanford Junior University

Trigemina, Inc.

Healthpartners Research Foundation

Tonix Pharmaceuticals Holding Corp.

Tonix Pharma Limited

Nocicepta LLC

Aarhus Universitet

Healthpartners Research & Education

Healthpartners Institute

David C Yeomans

Daniel Jacobs

Martin S Angst

William Howard Frey, Ii

Dean Carson

Brian M Andresen

Lawrence Robert Toll

Justin Du Bois

Ramachandran Thirucote

John Mulcahy

Sandip Biswal

Steen Jakobsen

Michael Winterdahl

Daria D Mochly-Rosen

Joan J Kendig

Sarah M Sweitzer

Erik Nguyen Nielsen

William H Frey

Daniel I Jacobs

Lawrence R Toll

Brian Andresen

William H Ii Frey

LABELED OXYTOCIN AND METHOD OF MANUFACTURE AND USE

Disclosed are methods and compositions for the treatment of autism spectrum disorder, related disorders and symptoms of such disorders, comprising co-administration of an oxytocin peptide and magnesium ions. Co-administration of an oxytocin peptide and magnesium ions results in a synergistic or enhanced effect on reducing social and communication deficits in a patient suffering from an autism spectrum disorder.

Magnesium-containing oxytocin formulations and methods of use

Disclosed areN-oxytocin molecules, methods of manufacture ofN-oxytocin molecules and methods of use ofN-oxytocin molecules in the determination of the distribution and kinetics ofN-oxytocin molecules after craniofacial or other application methods.

Labeled oxytocin and method of manufacture and use

Disclosed are magnesium-containing oxytocin peptide formulations or compositions comprising an oxytocin peptide and a magnesium salt that produces synergistic analgesia when used in treating pain. Also disclosed are methods for the treatment of pain (such as migraine headache) comprising co-administration of an oxytocin peptide and a magnesium salt.

Saxitoxin analogue compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogues, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analogue binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject. Also provided are methods for alleviating pain in a subject in need of treatment.

Methods and compositions for studying, imaging, and treating pain

The invention provides for methods and compositions for treatment of pain via craniofacial mucosal administration of an analgesic compound (e.g. a non-opioid analgesic peptide, an NOP agonist or N/OFQ). Intranasal administration of certain analgesic peptides such as N/OFQ results in global analgesic effects.

Methods for treatment of pain

Saxitoxin analog compounds, compositions, pharmaceutical compositions, methods of synthesis of saxitoxin analogs, methods of imaging, methods of treatment, including methods of treating pain, are provided. Saxitoxin (STX), gonyautoxin (GTX), and zetekitoxin, and variant STX compounds bind to sodium channels and are effective to reduce or block flow of sodium ions through such channels. Such channel block affects nerve and muscle action, and may be effective to reduce or block pain sensations, relax muscles, reduce muscle spasm, and reduce wrinkles. STX analog binding to sodium channels may also be useful to locate, image, or mark sodium channels, and so be useful in studying sodium channels and sodium channel disorders, and in the diagnosis and treatment of patients suffering from sodium channel disorders. In embodiments, the variant STX compounds include conjugates having increased serum half-life as compared to STX when administered to a subject. In embodiments, the present disclosure provides a method for alleviating pain in a subject in need of treatment, the method comprising administering to the subject an effective amount of a saxitoxin analog compound, or a pharmaceutically acceptable salt, isomer, tautomer or prodrug thereof, whereby pain in said subject is alleviated.

The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.

Methods for treatment of headaches by administration of oxytocin

The present invention relates to methods for the treatment or prevention of trigeminal nerve-associated pain, in particular chronic, acute and procedural-related pain. The methods comprise administration of analgesic agents to the trigeminal nerve system which results in analgesia to the facial or head region.

Therapy procedure for drug delivery for trigeminal pain

Peptide sequences derived from the V5 domain of isozymes of protein kinase C for use in pain management are described. Also described are compositions comprising the peptides for treating pain and/or inducing analgesia. Methods of pain treatment and methods of identifying compounds that mimic the activity of the peptides are also described.

Peptide inhibitors of protein kinase C &#x3b3; for pain management

Growing community of inventors

Sunnyvale, CA, United States of America

David C Yeomans